Unknown PHASE2 INTERVENTIONAL 1-arm NCT04705090

A Study of YY-20394 in Patients With Relapsed or Refractory Peripheral T/NK Cell Lymphoma

A Single-arm, Open, Multicenter, Phase II Study to Investigate the Efficacy and Safety of YY-20394 in Patients With Relapsed or Refractory Peripheral T/NK Cell Lymphoma

Sponsor: Shanghai YingLi Pharmaceutical Co. Ltd.

Conditions PTCL

Interventions YY-20394 treatment

Updated 4 times since 2021 Last updated: Jan 8, 2021 Started: Apr 30, 2021 Primary completion: Dec 31, 2022 Completion: Jun 30, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on PTCL, this trial is ongoing. The trial is conducted by Shanghai YingLi Pharmaceutical Co. Ltd. and has accumulated 4 data snapshots since 2021. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Jul 2023 — Jul 2024 [monthly]

Unknown Status PHASE2

Status: Not Yet Recruiting → Unknown Status
Feb 2021 — Jul 2023 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Shanghai YingLi Pharmaceutical Co. Ltd.

Data source: Shanghai YingLi Pharmaceutical Co. Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.